» Articles » PMID: 36159399

Application of Adipose-derived Mesenchymal Stem Cells in an Model of Peripheral Nerve Damage

Overview
Specialty Cell Biology
Date 2022 Sep 26
PMID 36159399
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuropathic pain is one of the most difficult to treat chronic pain syndromes. It has significant effects on patients' quality of life and substantially adds to the burden of direct and indirect medical costs. There is a critical need to improve therapies for peripheral nerve regeneration. The aim of this study is to address this issue by performing a detailed analysis of the therapeutic benefits of two treatment options: adipose tissue derived-mesenchymal stem cells (ASCs) and ASC-conditioned medium (CM).

Methods: To this end, we used an rat sciatic nerve damage model to investigate the molecular mechanisms involved in the myelinating capacity of ASCs and CM. Furthermore, effect of TNF and CM on Schwann cells (SCs) was evaluated. For our model, biomaterial surgical implants containing TNF were used to induce peripheral neuropathy in rats. Damaged nerves were also treated with either ASCs or CM and molecular methods were used to collect evidence of nerve regeneration. Post-operatively, rats were subjected to walking track analysis and their sciatic functional index was evaluated. Morphological data was gathered through transmission electron microscopy (TEM) of sciatic nerves harvested from the experimental rats. We also evaluated the effect of TNF on Schwann cells (SCs) . Genes and their correspondent proteins associated with nerve regeneration were analyzed by qPCR, western blot, and confocal microscopy.

Results: Our data suggests that both ASCs and CM are potentially beneficial treatments for promoting myelination and axonal regeneration. After TNF-induced nerve damage we observed an upregulation of c-Jun along with a downregulation of Krox-20 myelin-associated transcription factor. However, when CM was added to TNF-treated nerves the opposite effect occurred and also resulted in increased expression of myelin-related genes and their corresponding proteins.

Conclusion: Findings from our model showed that both ASCs and CM aided the regeneration of axonal myelin sheaths and the remodeling of peripheral nerve morphology.

Citing Articles

Multilevel analysis of the central-peripheral-target organ pathway: contributing to recovery after peripheral nerve injury.

Song X, Li R, Chu X, Li Q, Li R, Li Q Neural Regen Res. 2024; 20(10):2807-2822.

PMID: 39435615 PMC: 11826472. DOI: 10.4103/NRR.NRR-D-24-00641.


Stem cells and pain.

da Silva M, Piva M, Martelossi-Cebinelli G, Stinglin Rosa Ribas M, Hoffmann Salles Bianchini B, Heintz O World J Stem Cells. 2024; 15(12):1035-1062.

PMID: 38179216 PMC: 10762525. DOI: 10.4252/wjsc.v15.i12.1035.


The Effect of Adipose-Derived Mesenchymal Stem Cells on Peripheral Nerve Damage in a Rodent Model.

Yalcin M, Bora E, Erdogan M, Cakir A, Erbas O J Clin Med. 2023; 12(19).

PMID: 37835055 PMC: 10573691. DOI: 10.3390/jcm12196411.

References
1.
Lee S, Shi X, Fan A, West B, Zhang J . Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. Mol Pain. 2018; 14:1744806918764979. PMC: 5858622. DOI: 10.1177/1744806918764979. View

2.
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M . Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84. DOI: 10.1634/stemcells.22-3-377. View

3.
Perry V, Brown M, Gordon S . The macrophage response to central and peripheral nerve injury. A possible role for macrophages in regeneration. J Exp Med. 1987; 165(4):1218-23. PMC: 2188570. DOI: 10.1084/jem.165.4.1218. View

4.
OConnor A . Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009; 27(2):95-112. DOI: 10.2165/00019053-200927020-00002. View

5.
Chen Z, Yu W, Strickland S . Peripheral regeneration. Annu Rev Neurosci. 2007; 30:209-33. DOI: 10.1146/annurev.neuro.30.051606.094337. View